Oncology
NICE recommends SC treatment of AbbVie’s Tepkinly for patients with DLBCL
February 1, 2024Medical Communications AbbVie, DLBCL, NICE, Oncology, lymphoma
AbbVie has announced that the National Institute for Health and Care Excellence (NICE) has recommended Tepkinly (epcoritamab) as a treatment …
MHRA approves GSK’s Omjjara in Great Britain for splenomegaly treatment
January 31, 2024Medical Communications GSK, MHRA, Omjjara, Oncology, myelofibrosis, splenomegaly
GSK has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted Marketing Authorisation to Omjjara (momelotinib) in …
FDA clears IND for Gracell Biotechnologies’ phase 1 clinical trial for multiple myeloma treatment
January 30, 2024Research and Development FDA, Gracell Biotechnologies, Oncology, clinical trial, multiple myeloma
Gracell Biotechnologies has announced that the US Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application, …
Vergent Bioscience shares phase 2 data for VGT-309
January 29, 2024Research and Development Oncology, VGT-309, Vergent Bioscience, lung cancer
Vergent Bioscience has announced new data from a phase 2 trial of VGT-309, the company’s investigational tumour-targeted fluorescent imaging agent. …
Alphamab Oncology and 3DMedicines enter licensing agreement with Glenmark Speciality
January 25, 2024Medical Communications 3DMedicines, Alphamab Oncology, Glenmark Speciality, Oncology, envafolimab
Alphamb Oncology and 3DMedicines have announced that they have entered into a license agreement with Glenmark Speciality, a subsidiary of …
Onward Therapeutics announces enrolment of phase 1 trial of bispecific antibody
January 24, 2024Research and Development Oncology, Onward Therapeutics, bispecific antibody, clinical trial
Onward Therapeutics has announced that it has begun enrolment for its phase 1 clinical trial of OT-A201, a novel bispecific …
InnoCare announces first patient dosed in zurletrectinib clinical trial in China
January 24, 2024Research and Development InnoCare, Oncology, clinical trial, zurletrectinib
InnoCare Pharma has announced that the first paediatric patient has been dosed in a clinical trial of the company’s second …
FDA approves Balversa for bladder cancer treatment
January 22, 2024Medical Communications Balversa, FDA, Johnson & Johnson, Oncology, bladder cancer
Johnson & Johnson (J&J) have announced that the US Food and Drug Administration (FDA) has approved a supplemental New Drug …
Verastem Oncology gains Fast Track Designation for combination NSCLC treatment
January 19, 2024Medical Communications Cancer, FDA, NSCLC, Oncology, Verastem Oncology
Verastem Oncology has announced that the US Food and Drug Administration (FDA) has granted Fast Track Designation to the company’s …
FDA clears DermaSensor’s AI detection device for skin cancer
January 18, 2024Medical Communications FDA, Oncology, skin cancer
DermaSensor has announced that the US Food and Drug Administration (FDA) has granted clearance for its real-time, non-invasive skin cancer …
Arcus Biosciences shares results from phase 1b trial for pancreatic cancer treatment
January 18, 2024Medical Communications Arcus Biosciences, Oncology, Pancreatic cancer, clinical trial
Arcus Biosciences has announced new data from the ARC-8 phase 1b clinical study which is being co-developed alongside Gilead Sciences. …
Qlucore and Sahlgrenska Hospital sign agreement for ALL diagnosis software
January 17, 2024Business Services Oncology, Qlucore, Sahlgrenska Hospital, acute lymphoblastic leukaemia, leukaemia
Qlucore has announced that it has entered into an agreement with Sahlgrenska Hospital, in Gothenberg, Sweden. This agreement means the …
FDA approves Merck’s Keytruda with chemoradiotherapy as cervical cancer treatment
January 15, 2024Medical Communications FDA, Oncology, cervical cancer, keytruda
Merck, known as MSD outside of the US and Canada, has announced that the US Food and Drug Administration (FDA) …
Merck to acquire Harpoon Therapeutics for approximately $680m
January 10, 2024Business Services Harpoon Therapeutics, MSD, Merck, Oncology, acquisition
Merck (known as MSD outside of the US and Canada) and Harpoon Therapeutics have announced that they have entered a …
Fate Therapeutics initiates phase 1 trial for solid tumour treatment
January 9, 2024Research and Development Fate Therapeutics, Oncology, solid tumours
Fate Therapeutics has announced that it has begun enrollment for the phase 1 clinical trial of FT825/ONO-8250, a multiplexed-engineered, chimeric …
Latest content
FibroFind appoints Lee Borthwick as CEO
